🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Immunovant secures patent for autoimmune disease antibody

EditorEmilio Ghigini
Published 03/12/2024, 08:03 AM
© Reuters.

NEW YORK - Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company, has been granted a U.S. patent for its second-generation antibody, IMVT-1402, which targets autoimmune diseases. The U.S. Patent and Trademark Office issued Patent No. 11,926,669 with claims that include the composition of matter for the binding sequence of IMVT-1402 to the neonatal fragment crystallizable receptor (FcRn), its method of use in treating autoimmune diseases, and manufacturing methods.

The patent is set to expire on June 23, 2043, without accounting for any potential patent term extensions.

IMVT-1402, developed from HanAll Biopharma's antibody discovery efforts, has shown promise in a Phase 1 clinical trial involving healthy adults. The trial's initial results indicated a significant immunoglobulin G (IgG) reduction comparable to batoclimab, another antibody in the same class, but without notable changes in serum albumin and LDL cholesterol levels. Immunovant suggests that weekly administration of IMVT-1402 could maintain consistent IgG reductions, which may be crucial for sustained efficacy in patients.

The company's focus is on advancing therapies for the treatment of autoimmune diseases, aiming to improve the quality of life for affected individuals. However, it is important to note that early clinical trial results may not always be indicative of final outcomes, and further studies are required to confirm the safety and effectiveness of IMVT-1402.

Immunovant's progress in the development of IMVT-1402 and its patent acquisition represent steps forward in its quest to address the complex needs of people with autoimmune conditions. Nonetheless, the company acknowledges the inherent uncertainties and risks associated with drug development, including the need for additional capital and the challenges of navigating the regulatory landscape.

This news is based on a press release statement from Immunovant, Inc. Investors and stakeholders are reminded that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.